GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (LSE:HEMO) » Definitions » Short Interest

Hemogenyx Pharmaceuticals (LSE:HEMO) Short Interest


View and export this data going back to 2015. Start your Free Trial

What is Hemogenyx Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Hemogenyx Pharmaceuticals's Short Interest

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemogenyx Pharmaceuticals's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's Short Interest falls into.


Hemogenyx Pharmaceuticals (LSE:HEMO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (LSE:HEMO) » Definitions » Short Interest
Comparable Companies
LSE:OBI LSE:OPTI LSE:POLB LSE:SNG LSE:NSCI LSE:ONC LSE:C4XD LSE:BVX LSE:VAL LSE:ROQ OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
5HU:Germany
Address
60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Website
https://www.hemogenyx.com
Hemogenyx Pharmaceuticals PLC is a operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation / Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.

Hemogenyx Pharmaceuticals (LSE:HEMO) Headlines

No Headlines